Immuntherapiebedingte Nebenwirkungen
Author:
Publisher
Springer Science and Business Media LLC
Subject
Earth-Surface Processes
Link
https://link.springer.com/content/pdf/10.1007/s15012-023-7833-2.pdf
Reference8 articles.
1. Hassel JC et al. Combined immune checkpoint blockade (anti-PD-1/ anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treat Rev 2017;57:36-49
2. Schadendorf D et al. Efficacy and safety 0utcomes in patients with advanced melanoma who discontinued treatment with Nivolumab and Ipilimumab because of adverse events: A pooled analysis of randomized Phase II and III trials. J Clin Oncol 2017;35:3807-14
3. Eggermont AMM et al. Association between immmune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive Pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol 2020;6:519-27
4. Schneider BJ et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 2021;39:4073-126
5. Haanen J et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Annals of Oncology 2022;33:1217-38
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3